The Seventh Report of the Joint
National Committee on Prevention,
Detection, Evaluation, and Treatment
of High Blood Pressure
The JNC 7 Report
“The Seventh Report of the Joint National Committee on Prevention, De-
tection, Evaluation, and Treatment of High Blood Pressure” provides a new
guideline for hypertension prevention and management. The following are
the key messages: (1) In persons older than 50 years, systolic blood pres-
sure (BP) of more than 140 mm Hg is a much more important cardiovascular
disease (CVD) risk factor than diastolic BP; (2) The risk of CVD, beginning
at 115/75 mm Hg, doubles with each increment of 20/10 mm Hg; individu-
als who are normotensive at 55 years of age have a 90% lifetime risk for
developing hypertension; (3) Individuals with a systolic BP of 120 to 139

mm Hg or a diastolic BP of 80 to 89 mm Hg should be considered as pre-
hypertensive and require health-promoting lifestyle modifications to pre-
vent CVD; (4) Thiazide-type diuretics should be used in drug treatment for
most patients with uncomplicated hypertension, either alone or combined
with drugs from other classes. Certain high-risk conditions are compelling
indications for the initial use of other antihypertensive drug classes (angio-
tensin-converting enzyme inhibitors, angiotensin-receptor blockers, -block-
OR MORE THAN 3 DECADES, THENational Heart, Lung, and ers, calcium channel blockers); (5) Most patients with hypertension will re-
quire 2 or more antihypertensive medications to achieve goal BP (Ͻ140/90
mm Hg, or Ͻ130/80 mm Hg for patients with diabetes or chronic kidney
disease); (6) If BP is more than 20/10 mm Hg above goal BP, consideration
should be given to initiating therapy with 2 agents, 1 of which usually should
be a thiazide-type diuretic; and (7) The most effective therapy prescribed by
the most careful clinician will control hypertension only if patients are mo-
organizations and 7 federal agencies.
One important function is to issue tivated. Motivation improves when patients have positive experiences with
and trust in the clinician. Empathy builds trust and is a potent motivator.
Finally, in presenting these guidelines, the committee recognizes that the
responsible physician’s judgment remains paramount.
publication of “The Sixth Report ofthe Joint National Committee on thePrevention, Detection, Evaluation, and Author Affiliations and Financial Disclosures are listed
Corresponding Author and Reprints: Edward J. Roc-
cella, PhD, MPH, National Heart, Lung, and Blood In- stitute, National Institutes of Health, 31 Center Dr, MSC2480, Bethesda, MD 20892 (e-mail: roccella@nih See also pp 2534 and 2573.
tee for “The Seventh Report of the Joint 2560 JAMA, May 21, 2003—Vol 289, No. 19 (Reprinted)
2003 American Medical Association. All rights reserved.
tee members provide in writing a detailed rationale explaining the necessity to up- sidered for a new report. The JNC 7 chair plify the classification of BP; and a clear reviewed in a reiterative fashion. At its discussion and justification for the cur- Classification of BP
TABLE 1 provides a classification of BP
chaired by the director of the NHLBI, has pertension clinical trials at their bian- reviewed scientific literature from Janu- readings on each of 2 or more office vis- principal investigator of the larger stud- rectly to the Coordinating Committee.
Table 1. Classification and Management of Blood Pressure for Adults Aged 18 Years or Older
Initial Drug Therapy
BP, mm Hg*
BP, mm Hg*
Without Compelling Indication
With Compelling Indications†
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; BP, blood pressure; CCB, calcium channel blocker.
*Treatment determined by highest BP category.
†See Table 6.
‡Treat patients with chronic kidney disease or diabetes to BP goal of less than 130/80 mm Hg.
§Initial combined therapy should be used cautiously in those at risk for orthostatic hypotension.
2003 American Medical Association. All rights reserved.
(Reprinted) JAMA, May 21, 2003—Vol 289, No. 19 2561
Table 2. Trends in Awareness, Treatment, and Control of High Blood Pressure in Adults With
National Health and Nutrition Examination Surveys, Weighted %
III (Phase 1,
III (Phase 2,
II (1976-1980)
Accurate BP Measurement
*Data for 1999-2000 were computed (M. Wolz, unpublished data, 2003) from the National Heart, Lung, and Blood Institute and data for National Health and Nutrition Examination Surveys II and III (phases 1 and 2) are from “The Sixth in the Office
Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pres-sure.”1 High blood pressure is systolic blood pressure of at least 140 mm Hg or diastolic blood pressure of at least 90 mm Hg or taking antihypertensive medication.
†Systolic blood pressure of less than 140 mm Hg and diastolic blood pressure of less than 90 mm Hg.
validated instrument should be used.16Patients should be seated quietly for at least 5 minutes in a chair rather than on floor and arm supported at heart level.
Benefits of Lowering BP
cially in those at risk for postural hypo- Cardiovascular Disease Risk
It is estimated that in patients with stage years of age have a 90% lifetime risk for Ambulatory BP Monitoring
BP Control Rates
35 million office visits as the primary di- Ͻ90 mm Hg), although improved, are with antihypertensive medications, epi- have hypertension (TABLE 2). In the ma-
usually lower than clinic readings. Awake jority of patients, controlling systolic hy- introduced in this report (Table 1), rec- ognizes this relationship and signals the toring correlates better than office mea- tolic hypertension. Recent clinical trials readings that are elevated, the overall BP load, and the extent of BP reduction dur- 2562 JAMA, May 21, 2003—Vol 289, No. 19 (Reprinted)
2003 American Medical Association. All rights reserved.
ing sleep. In most individuals, BP de-creases by 10% to 20% during the night; Box 1. Cardiovascular Risk Factors*
Major Risk Factors
present are at increased risk for cardio- Self-measurement of BP
Microalbuminuria or estimated GFR Ͻ60 mL /min Age (Ͼ55 years for men, Ͼ65 years for women) Family history of premature cardiovascular disease (men Ͻ55 years Target-Organ Damage
Prior coronary revascularizationHeart failure Patient Evaluation
(1) to assess lifestyle and identify other *BMI indicates body mass index calculated as weight in kilograms divided by the square of height in meters; GFR, glomerular filtration rate.
sis and guide treatment (BOX 1); (2) to
†Components of the metabolic syndrome.
reveal identifiable causes of high BP
(BOX 2); and (3) to assess the presence
or absence of target-organ damage and
Box 2. Identifiable Causes of
tration rate), and calcium20; and a lipid profile (after a 9- to 12-hour fast) that with verification in the contralateral arm; lesterol, and triglycerides. Optional tests ally unless BP control is not achieved.
cultation for carotid, abdominal, andfemoral bruits; palpation of the thyroid Treatment
Goals of Therapy.The ultimate public
pulses; and neurological assessment.
Lifestyle Modifications. Adoption of
Laboratory Tests and
critical for the prevention of high BP and Other Diagnostic Procedures
tolic BP goal (FIGURE). Treating sys-
tolic BP and diastolic BP to targets that 2003 American Medical Association. All rights reserved.
(Reprinted) JAMA, May 21, 2003—Vol 289, No. 19 2563
(TABLE 3).30 Lifestyle modifications de-
Pharmacologic Treatment. Excel-
pertension eating plan has effects similar converting enzyme (ACE) inhibitors,angiotensin-receptor blockers (ARBs), Figure. Algorithm for Treatment of Hypertension
(CCBs), and thiazide-type diuretics, willall reduce the complications of hyper- tension.10,31-37 TABLE 4 and TABLE 5 pro-
vide a list of commonly used antihy-
(<140/90 mm Hg or <130/80 mm Hg for Those With Diabetes basis of antihypertensive therapy in most outcome trials.37 In these trials, includ-ing the recently published Antihyper- to Prevent Heart Attack Trial,33 diuret-ics have been virtually unsurpassed in Pressure trial36 that reported slightly bet- ter outcomes in white men with a regi-men that began with an ACE inhibitorcompared with one starting with a di- uretic. Diuretics enhance the antihyper-tensive efficacy of multidrug regimens, Optimize Dosages or Add Additional Drugs Until Goal BP Is Achieved can be useful in achieving BP control, and Consider Consultation With Hypertension Specialist are more affordable than other antihy-pertensive agents. Despite these find- BP indicates blood pressure; ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; and CCB,calcium channel blocker.
as initial therapy for most patients with Table 3. Lifestyle Modifications to Manage Hypertension*
Approximate Systolic BP
Reduction, Range
Maintain normal body weight (BMI, 18.5-24.9) Consume a diet rich in fruits, vegetables, and Reduce dietary sodium intake to no more than as initial therapy are listed in TABLE 6.
If a drug is not tolerated or is contrain- Engage in regular aerobic physical activity dicated, then 1 of the other classes proven such as brisk walking (at least 30 minutes Limit consumption to no more than 2 drinks per day (1 oz or 30 mL ethanol [eg, 24 oz Achieving BP Control in Indi-
vidual Patients. Most patients with hy-
whiskey]) in most men and no more than1 drink per day in women and hypertensive medications to achieve their Abbreviations: BMI, body mass index calculated as weight in kilograms divided by the square of height in meters; BP, blood pressure; DASH, Dietary Approaches to Stop Hypertension.
*For overall cardiovascular risk reduction, stop smoking. The effects of implementing these modifications are dose and time dependent and could be higher for some individuals.
2564 JAMA, May 21, 2003—Vol 289, No. 19 (Reprinted)
2003 American Medical Association. All rights reserved.
equate doses fails to achieve the BP goal.
tions already in use, tolerability, and de- sired BP targets. In many cases, specialist above goal, consideration should be given Ischemic Heart Disease. Ischemic
ther as separate prescriptions or in fixed- ␤-blocker; alternatively, long-acting nists have proven to be most benefi- vised in those at risk for orthostatic hy-potension, such as patients with diabe- Table 4. Oral Antihypertensive Drugs*
Usual Dose,
Drug (Trade Name)
Range, mg/d
Follow-up and Monitoring. Once an-
frequent visits will be necessary for pa- year.60 After BP is at goal and stable, fol- treated to their respective goals, and to- Special Considerations
tention and follow-up by the clinician.
Compelling Indications. Table 6 de-
classes for high-risk conditions. The drug data from clinical trials. Combination of 2003 American Medical Association. All rights reserved.
(Reprinted) JAMA, May 21, 2003—Vol 289, No. 19 2565
Heart Failure. Heart failure, in the
Diabetic Hypertension. Combina-
Chronic Kidney Disease. In pa-
filtration rate of less than 60 mL/min per tion, ACE inhibitors and ␤-blockers are tients with diabetes.33,54,63 The ACE in- µmol/L] in women)20 or (2) the pres-ence of albuminuria (Ͼ300 mg/d or 200mg albumin per gram of creatinine), Table 4. Oral Antihypertensive Drugs (cont)*
Usual Dose,
Drug (Trade Name)
Range, mg/d
tion of renal function and prevent CVD.
betic renal disease.55-59,64 A limited in- Cerebrovascular Disease. The risks
and benefits of acute lowering of BP dur- ing an acute stroke are still unclear; con- trol of BP at intermediate levels (approxi- until the condition has stabilized or im- Other Special Situations. Minority
Populations. Blood pressure control rates Abbreviation: ACE, angiotensin-converting enzyme.
*Dosages may vary from those listed in the Physicians’ Desk Reference,38 which may be consulted for additional in- †Are now or will soon become available in generic preparations.
‡A 0.1-mg dose may be given every other day to achieve this dosage.
2566 JAMA, May 21, 2003—Vol 289, No. 19 (Reprinted)
2003 American Medical Association. All rights reserved.
est rates of BP control.68 Treatment rec- Hypertension in Older Individuals. Hy- thirds of individuals after age 65 years.1 This is also the population with the low- to monotherapy with ␤-blockers, ACEinhibitors, or ARBs compared with di- Table 5. Combination Drugs for Hypertension
Combination Type
Fixed-Dose Combination, mg*
Trade Name
Obesity and the Metabolic Syndrome. development of hypertension and CVD.
conditions: abdominal obesity (waist cir- Candesartan cilexetil/hydrochlorothiazide each of its components as indicated.
Left Ventricular Hypertrophy. Left ven- risk factor that increases the risk of sub- Peripheral Arterial Disease. Periph- eral arterial disease is equivalent in risk Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; CCB, calcium channel blocker; HCl, hydrochloride; HCT, hydrochlorothiazide; LA, long-acting.
*Some drug combinations are available in multiple fixed doses. Each drug dose is reported in milligrams.
2003 American Medical Association. All rights reserved.
(Reprinted) JAMA, May 21, 2003—Vol 289, No. 19 2567
greater adjusted for age, height, and sex.73 traception. In contrast, hormone replace- define diastolic BP. Clinicians should be Postural Hypotension. A decrease in fully because of increased risks to mother vasodilators are preferred medications for cologic therapy instituted for higher lev- ics, venodilators (eg, nitrates, ␣-block- ers, and sildenafil-like drugs), and some cause of the potential for fetal defects and similar in children and adults, but effec- tive doses for children are often smaller physical activities, particularly because monitoring, early fetal delivery, and par- Hypertension in Women. Oral contra- modifiable risk factors (eg, smoking).
Children and Adolescents. In chil- Hypertensive Urgencies and Emergen- cies. Patients with marked BP eleva- Table 6. Clinical Trial and Guideline Basis for Compelling Indications for Individual Drug Classes
Recommended Drugs
High-Risk Conditions
With Compelling
Clinical Trial Basis†
MERIT-HF,41 COPERNICUS,42 CIBIS,43SOLVD,44 AIRE,45 TRACE,46 ValHEFT,47RALES48 NKF-ADA Guideline,21,22 UKPDS,54 ALLHAT33 NKF Guideline,22 Captopril Trial,55 RENAAL,56 Abbreviations: AASK, African American Study of Kidney Disease and Hypertension; ACC/AHA, American College of Cardiology/American Heart Association; ACE, angiotensin- converting enzyme; AIRE, Acute Infarction Ramipril Efficacy; ALLHAT, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; ANBP2, Second AustralianNational Blood Pressure Study; ARB, angiotensin-receptor blocker; BHAT, ␤-Blocker Heart Attack Trial; CCB, calcium channel blocker; CIBIS, Cardiac Insufficiency BisoprololStudy; CONVINCE, Controlled Onset Verapamil Investigation of Cardiovascular End Points; COPERNICUS, Carvedilol Prospective Randomized Cumulative Survival Study;EPHESUS, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study; HOPE, Heart Outcomes Prevention Evaluation Study; IDNT, Inbesartan Dia-betic Nephropathy Trial; LIFE, Losartan Intervention For Endpoint Reduction in Hypertension Study; MERIT-HF, Metoprolol CR/XL Randomized Intervention Trial in CongestiveHeart Failure; NKF-ADA, National Kidney Foundation–American Diabetes Association; PROGRESS, Perindopril Protection Against Recurrent Stroke Study; RALES, RandomizedAldactone Evaluation Study; REIN, Ramipril Efficacy in Nephropathy Study; RENAAL, Reduction of Endpoints in Non–Insulin-Dependent Diabetes Mellitus with the Angiotensin IIAntagonist Losartan Study; SAVE, Survival and Ventricular Enlargement Study; SOLVD, Studies of Left Ventricular Dysfunction; TRACE, Trandolapril Cardiac Evaluation Study;UKPDS, United Kingdom Prospective Diabetes Study; ValHEFT, Valsartan Heart Failure Trial.
*Compelling indications for antihypertensive drugs are based on benefits from outcome studies or existing clinical guidelines; the compelling indication is managed in parallel with †Conditions for which clinical trials demonstrate benefit of specific classes of antihypertensive drugs.
2568 JAMA, May 21, 2003—Vol 289, No. 19 (Reprinted)
2003 American Medical Association. All rights reserved.
tions and acute target-organ damage(eg, encephalopathy, myocardial in- Box 3. Causes of Resistant Hypertension
life-threatening arterial bleeding, or aor- Nonsteroidal anti-inflammatory drugs; cyclooxygenase 2 inhibitors Cocaine, amphetamines, other illicit drugs Sympathomimetics (decongestants, anorectics) able causes of hypertension (Box 2).
Additional Considerations in Anti-
hypertensive Drug Choices. Antihyper-
Licorice (including some chewing tobacco) Selected over-the-counter dietary supplements and medicines (eg, ephedra, favorable effects on other comorbidities.
Potential Favorable Effects. Thiazide- mineralization in osteoporosis. ␤-Block- Identifiable causes of hypertension (see Box 2) ers can be useful in the treatment ofatrial tachyarrhythmias/fibrillation, mi-graine, thyrotoxicosis (short-term), es-sential tremor, or perioperative hyper- if the patient is motivated to take the pre- ing can also be useful. Patients’ nonad- maintain a health-promoting lifestyle.
Potential Unfavorable Effects. Thia- as symbols of ill health, lack of patient pected adverse effects of medications.
asthma, reactive airways disease, or sec- fortable in telling the clinician all con- stood if the clinician is to build trust and tions, despite knowing the patient is not at goal BP, represents clinical inertia and Improving Hypertension Control
Adherence to Regimens. Behavioral
tion of the time needed to reach the goal force instructions to improve patients’ 2003 American Medical Association. All rights reserved.
(Reprinted) JAMA, May 21, 2003—Vol 289, No. 19 2569
Resistant Hypertension. Resistant
ter, Memphis (Dr Cushman); Department of Family (Mayo Clinic and Mayo Medical School, Rochester, Medicine, University of Michigan, Ann Arbor (Dr Minn); Gerald J. Wilson, MA, MBA (Citizens for Public hypertension is the failure to reach goal Green); Department of Medicine and Pharmacology, Action on High Blood Pressure and Cholesterol, Inc, State University of New York at Buffalo School of Medi- Potomac, Md); Mary Winston, EdD, RD (American Heart cine, Buffalo (Dr Izzo); Department of Medicine and Association, Dallas, Tex); Jackson T. Wright, Jr, MD, Center for Excellence in Cardiovascular-Renal Re- PhD (Case Western Reserve University, Cleveland, Ohio); search, University of Mississippi Medical Center, Jack- Staff: Joanne Karimbakas, MS, RD (American Insti- son (Dr Jones); Department of Medicine, University tutes for Research Health Program, Silver Spring, Md).
of Miami School of Medicine, Miami, Fla (Dr Mater- Financial Disclosures: The following authors have re-
son); Department of Medicine, Physiology, and Bio- ceived honoraria for serving as a speaker: Dr Choba- physics, Division of Cardiovascular Disease, Univer- nian (Monarch, Wyeth, Astra-Zeneca, Solvay, Bristol- tient is not at goal BP (B
sity of Alabama at Birmingham (Dr Oparil); Myers Squibb); Dr Bakris (Astra-Zeneca, Abbott, OX 3). Particu-
Departments of Medicine, University Hospitals of Alteon, Biovail, Boerhinger-Ingelheim, Bristol-Myers Cleveland and the Louis Stokes Cleveland Veterans Squibb, Forest, GlaxoSmithKline, Merck, Novartis, Sa- uretic type and dose in relation to renal Affairs Medical Center, Cleveland, Ohio (Dr Wright); nofi, Sankyo, Solvay); Dr Black (Astra-Zeneca, Bristol- and National High Blood Pressure Education Pro- Myers Squibb, Novartis, Pfizer, Pharmacia, Wyeth- gram, National Heart, Lung, and Blood Institute, Na- Ayerst); Dr Izzo (Boehringer-Ingelheim, Merck, Pfizer, ease” section). Consultation with a hy- tional Institutes of Health, Bethesda, Md (Dr Roccella).
Astra-Zeneca, Solvay, Novartis, Forest, Sankyo); Dr Additional Authors/National High Blood Pressure Edu-
Sowers (Med Com Vascular Biology Working Group, cation Program Coordinating Committee Partici-
Joslin Clinic Foundation); Dr Wright (Astra, Aventis, pants: Claude Lenfant, MD, chair (National Heart, Lung,
Bayer, Bristol-Myers Squibb, Forest, Merck, Norvar- and Blood Institute, Bethesda, Md); George L. Bakris, tis, Pfizer, Phoenix Pharmaceuticals, GlaxoSmith- MD, Henry R. Black, MD (Rush Presbyterian-St Luke’s Public Health Challenges
Medical Center, Chicago, Ill); Barry L. Carter, PharmD The following authors have received funding/grant and Community Programs
(University of Iowa, Iowa City); Jerome D. Cohen, MD support for research projects: Dr Bakris (National Insti- (St Louis University School of Medicine, St Louis, Mo); tutes of Health, Astra-Zeneca, Abbott, Alteon, Boer- Pamela J. Colman, DPM (American Podiatric Medical hinger-Ingelheim, Forest, GlaxoSmithKline, Merck, ducing calories, saturated fat, and salt in Association, Bethesda, Md); William C. Cushman, MD Novartis, Sankyo, Solvay); Dr Black (Bristol-Myers (Veterans Affairs Medical Center, Memphis, Tenn); Mark Squibb, Boehringer-Ingelheim, Merck, Pfizer, Pharma- J. Cziraky, PharmD (Health Core, Inc, Newark, Del); John cia); Dr Cushman (Astra-Zeneca, Merck, Pfizer, Kos, J. Davis, PA-C (American Academy of Physician Assis- Aventis Pharma, King Pharmaceuticals, GlaxoSmith- tants, Memphis, Tenn); Keith Copelin Ferdinand, MD Kline, Boehringer-Ingelheim); Dr Izzo (Boehringer- (Heartbeats Life Center, New Orleans, La); Ray W. Gif- Ingelheim, Merck, Astra-Zeneca, Novartis, GlaxoSmith- ward shift in the distribution of a popu- ford, Jr, MD (Cleveland Clinic Foundation, Fountain Hills, Kline, Biovail); Dr Oparil (Abbott Laboratories, Astra- Ariz); Michael Glick, DMD (UMDNJ, New Jersey Den- Zeneca, Aventis, Boehringer-Ingelheim, Bristol-Myers tal School, Newark); Lee A. Green, MD, MPH (Univer- Squibb, Eli Lilly, Forest, GlaxoSmithKline, Monarch, sity of Michigan, Ann Arbor); Stephen Havas, MD, MPH, Novartis [Ciba], Merck, Pfizer, Sanofi/BioClin, Scher- MS (University of Maryland School of Medicine, Bal- ing Plough, Schwarz Pharma, Scios Inc, GD Searle, Wy- timore); Thomas H. Hostetter, MD (National Institute eth-Ayerst, Sankyo, Solvay, Texas Biotechnology Cor- of Diabetes and Digestive and Kidney Diseases, Bethesda, poration); Dr Sowers (Novartis, Astra-Zeneca); Dr Wright Md); Joseph L. Izzo, Jr, MD (State University of New (Astra, Aventis, Bayer, Biovail, Bristol-Myers Squibb, For- als in the United States has increased to York at Buffalo School of Medicine, Buffalo); Daniel W.
est, Merck, Norvartis, Pfizer, Phoenix Pharmaceuti- Jones, MD (University of Mississippi Medical Center, cals, GlaxoSmithKline, Solvay/Unimed).
Jackson); Lynn Kirby, RN, NP, COHNS (Sanofi- The following authors have served as a consultant/ Synthelabo Research, Malvern, Pa); Kathryn M. Kolasa, advisor: Dr Bakris (Astra-Zeneca, Abbott, Alteon, PhD, RD, LDN (Brody School of Medicine at East Caro- Biovail, Boerhinger-Ingelheim, Bristol-Myers Squibb, lina University, Greenville, NC); Stuart Linas, MD (Uni- Forest, GlaxoSmithKline, Merck, Novartis, Sanofi, San- versity of Colorado Health Sciences Center, Denver); kyo, Solvay); Dr Black (Abbott, Astra-Zeneca, Biovail, William M. Manger, MD, PhD (New York University Bristol-Myers Squibb, GlaxoSmithKline, Merck, Pfizer, Medical Center, New York); Edwin C. Marshall, OD, Pharmacia); Dr Carter (Bristol-Myers Squibb); Dr Cush- MS, MPH (Indiana University School of Optometry, man (Bristol-Myers Squibb, Sanofi, GlaxoSmithKline, Bloomington); Barry J. Materson, MD, MBA (Univer- Novartis, Pfizer, Solvay, Pharmacia, Takeda, Sankyo, sity of Miami, Miami, Fla); Jay Merchant, MHA (Cen- Forest, Biovail); Dr Izzo (Merck, Astra-Zeneca, Novar- ters for Medicare and Medicaid Services, Washington, tis, Intercure, Sankyo, Nexcura); Dr Jones (Pfizer, Bristol- DC); Nancy Houston Miller, RN, BSN (Stanford Uni- Myers Squibb, Merck, Forest, Novartis); Dr Manger versity School of Medicine, Palo Alto, Calif ); Marvin (NHBPEP Coordinating Committee); Dr Materson Moser, MD (Yale University School of Medicine, (Unimed, Merck, GlaxoSmithKline, Novartis, Reliant, of racial, ethnic, cultural, linguistic, re- Scarsdale, NY); William A. Nickey, DO (Philadelphia Col- Tanabe, Bristol-Myers Squibb, Pfizer, Pharmacia, No- ligious, and social factors in the deliv- lege of Osteopathic Medicine, Philadelphia, Pa); Suzanne ven, Boehringer-Ingelheim, Solvay); Dr Oparil (Bristol- Oparil, MD (University of Alabama at Birmingham); Ote- Myers Squibb, Merck, Pfizer, Sanofi, Novartis, The Salt lio S. Randall, MD (Howard University Hospital, Wash- ington, DC); James W. Reed, MD (Morehouse School The following author has stock holdings: Dr Izzo (In- of Medicine, Atlanta, Ga); Edward J. Roccella, PhD, MPH (National Heart, Lung, and Blood Institute, Bethesda, Dr Oparil is also on the Board of Directors for the Md); Lee Shaughnessy (National Stroke Association, Englewood, Colo); Sheldon G. Sheps, MD (Mayo Clinic, The NHBPEP Coordinating Committee Thanks the Fol-
Rochester, Minn); David B. Snyder, RPh, DDS (Health lowing Reviewers: William B. Applegate, MD, MPH
Resources and Services Administration, Rockville, Md); (Wake Forest University School of Medicine, Wins- James R. Sowers, MD (SUNY Health Science Center at ton Salem, NC); Jan N. Basile, MD (Veterans Admin- Brooklyn, Brooklyn, NY); Leonard M. Steiner, MS, OD istration Hospital, Charleston, SC); Robert Carey, MD (Eye Group, Oakhurst, NJ); Ronald Stout, MD, MPH (University of Virginia Health System, Charlottes- Author Affiliations: Department of Medicine, Bos-
(Procter and Gamble, Mason, Ohio); Rita D. Strick- ville, Va); Victor Dzau, MD (Brigham and Women’s ton University School of Medicine, Boston, Mass (Dr land, EdD, RN (New York Institute of Technology, Hospital, Boston, Mass); Brent M. Egan, MD (Medi- Chobanian); Department of Preventive Medicine, Springfield Gardens, NY); Carlos Vallbona, MD (Bay- cal University of South Carolina, Charleston, SC); Bo- Rush-Presbyterian-St Luke’s Medical Center, Chi- lor College of Medicine, Houston, Tex); Howard S. Weiss, nita Falkner, MD ( Jefferson Medical College, Phila- cago, Ill (Drs Bakris and Black); Veterans Affairs Medi- MD, MPH (Georgetown University Medical Center, delphia, Pa); John M. Flack, MD, MPH (Wayne State cal Center, Departments of Preventive Medicine and Washington Hospital Center, Walter Reed Army Medi- University School of Medicine, Detroit, Mich); Ed- Medicine, University of Tennessee Health Science Cen- cal Center, Washington, DC); Jack P. Whisnant, MD ward D. Frohlich, MD (Ochsner Clinic Foundation, New 2570 JAMA, May 21, 2003—Vol 289, No. 19 (Reprinted)
2003 American Medical Association. All rights reserved.
Orleans, La); Haralambos Gavras, MD (Boston Uni-versity School of Medicine, Boston, Mass); Martin Grais,MD (Feinberg School of Medicine, Northwestern Uni- Scheme Used for Classification of the Evidence
versity, Chicago, Ill); Willa A. Hsueh, MD (David Gef- Meta-analysis; use of statistical methods to combine the results from clinical fen School of Medicine, University of California at Los Angeles); Kenneth A. Jamerson, MD (University ofMichigan Medical Center, Ann Arbor); Norman M.
Ra Randomized controlled trials; also known as experimental studies
Kaplan, MD (University of Texas Southwestern Medi- Re Retrospective analyses; also known as case-control studies
cal Center, Dallas); Theodore A. Kotchen, MD (Medi- Prospective study; also known as cohort studies, including historical or pro- cal College of Wisconsin, Milwaukee); Daniel Levy,MD (National Heart, Lung, and Blood Institute, Framingham, Mass); Michael A. Moore, MD (Wake Cross-sectional survey; also known as prevalence studies Forest University School of Medicine and Dan River Pr Previous review or position statements
Region Cardiovascular Health Initiative Program, Dan- ville, Va); Thomas J. Moore, MD (Boston UniversityMedical Center, Boston, Mass); Vasilios Papademe-triou, MD (Veterans Administration Medical Center, These symbols are appended to the citations in the reference list. The studies that Washington, DC); Carl J. Pepine, MD (University of provided evidence supporting the recommendations of this report were classified Florida, College of Medicine, Gainesville, Fla); Rob- and reviewed by the staff and the executive committee. The classification scheme ert A. Phillips, MD, PhD (New York University, Lenox Hill Hospital, New York); Thomas G. Pickering, MD,DPhil (Mount Sinai Medical Center, New York, NY);L. Michael Prisant, MD (Medical College of Georgia,Augusta); C. Venkata S. Ram, MD (University of TexasSouthwestern Medical Center and Texas Blood Pres- sure Institute, Dallas); Elijah Saunders, MD (Univer- REFERENCES
Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse sity of Maryland School of Medicine, Baltimore); Ste- 1. Joint National Committee on Prevention Detec-
North American settings: The Antihypertensive and phen C. Textor, MD (Mayo Clinic, Rochester, Minn); tion, Evaluation, and Treatment of High Blood Pres- Lipid-Lowering Treatment to Prevent Heart Attack Trial Donald G. Vidt, MD (Cleveland Clinic Foundation, sure. The sixth report of the Joint National Commit- (ALLHAT). J Clin Hypertens (Greenwich). 2002;4: Cleveland, Ohio); Myron H. Weinberger, MD (Indi- tee on Prevention, Detection, Evaluation, and 393-404. Ra
ana University School of Medicine, Indianapolis); Paul Treatment of High Blood Pressure. Arch Intern Med. 15. Black HR, Elliott WJ, Neaton JD, et al. Baseline
K. Whelton, MD, MSc (Tulane University Health Sci- 1997;157:2413-2446. Pr
characteristics and elderly blood pressure control in 2. US Department of Health and Human Services, Na-
the CONVINCE trial. Hypertension. 2001;37:12-18.
Funding/Support: This work was supported entirely
tional Heart, Lung, and Blood Institute. National High by the National Heart, Lung, and Blood Institute. The Blood Pressure Education Program. Available at: http: 16. World Hypertension League. Measuring your
executive committee, writing teams, and reviewers //www.nhlbi.nih.gov/about/nhbpep/index.htm. Ac- blood pressure. Available at: http://www.mco.edu served as volunteers without remuneration.
/org/whl/bloodpre.html. Accessed April 1, 2003.
The NHBPEP Coordinating Committee Includes Rep-
3. Sheps SG, Roccella EJ. Reflections on The Sixth
17. Pickering T. Recommendations for the use of home
resentatives From the Following Member Organiza-
Report of the Joint National Committee on Preven- (self ) and ambulatory blood pressure monitoring. Am tions: American Academy of Family Physicians; Ameri-
tion, Detection, Evaluation, and Treatment of High J Hypertens. 1996;9:1-11. Pr
can Academy of Neurology; American Academy of Blood Pressure. Curr Hypertens Rep. 1999;1:342- 18. Verdecchia P. Prognostic value of ambulatory
Ophthalmology; American Academy of Physician Assis- blood pressure. Hypertension. 2000;35:844-851. Pr
tants; American Association of Occupational Health 4. Roccella EJ, Kaplan NM. Interpretation and evalu-
19. American Heart Association. Home monitoring of
Nurses; American College of Cardiology; American Col- ation of clinical guidelines. In: Izzo JL Jr, Black HR, eds.
high blood pressure. Available at: http://www lege of Chest Physicians; American College of Occu- Hypertension Primer. Dallas, Tex: American Heart As- .americanheart.org/presenter.jhtml?identifier=576. Ac- pational and Environmental Medicine; American Col- sociation; 2003:126-127. Pr
lege of Physicians-American Society of Internal Medicine; 5. Last JM, Abramson JH, eds. A Dictionary of Epi-
20. Calculators and modeling aids. GFR/1.73 M2 by
American College of Preventive Medicine; American demiology. 3rd ed. New York, NY: Oxford Univer- MDRD (±SUN and SAlb). Available at: http://www Dental Association; American Diabetes Association; .hdcn.com/calcf/gfr.htm. Accessed April 1, 2003.
American Dietetic Association; American Heart Asso- 6. Vasan RS, Larson MG, Leip EP, et al. Assessment
21. American Diabetes Association. Treatment of hy-
ciation; American Hospital Association; American Medi- of frequency of progression to hypertension in non- pertension in adults with diabetes. Diabetes Care. 2003; cal Association; American Nurses Association; Ameri- hypertensive participants in The Framingham Heart 26(suppl 1):S80-S82. Pr
can Optometric Association; American Osteopathic Study. Lancet. 2001;358:1682-1686. F
22. National Kidney Foundation Guideline. K/DOQI
Association; American Pharmaceutical Association; 7. Vasan RS, Beiser A, Seshadri S, et al. Residual life-
clinical practice guidelines for chronic kidney disease: American Podiatric Medical Association; American Pub- time risk for developing hypertension in middle-aged Kidney Disease Outcome Quality Initiative. Am J Kid- lic Health Association; American Red Cross; American women and men: The Framingham Heart Study.
ney Dis. 2002;39(suppl 2):S1-S246. Pr
Society of Health-System Pharmacists; American Soci- JAMA. 2002;287:1003-1010. F
23. The Trials of Hypertension Prevention Collabo-
ety of Hypertension; American Society of Nephrology; 8. Lewington S, Clarke R, Qizilbash N, Peto R, Collins
rative Research Group. Effects of weight loss and Association of Black Cardiologists; Citizens for Public R. Age-specific relevance of usual blood pressure to vas- sodium reduction intervention on blood pressure and Action on High Blood Pressure and Cholesterol, Inc; cular mortality. Lancet. 2002;360:1903-1913. M
hypertension incidence in overweight people with high- Hypertension Education Foundation, Inc; Interna- 9. Whelton PK, He J, Appel LJ, et al. Primary preven-
normal blood pressure. Arch Intern Med. 1997;157: tional Society on Hypertension in Blacks; National Black tion of hypertension: clinical and public health advi- 657-667. Ra
Nurses Association, Inc; National Hypertension Asso- sory from The National High Blood Pressure Educa- 24. He J, Whelton PK, Appel LJ, Charleston J, Klag
ciation, Inc; National Kidney Foundation, Inc; National tion Program. JAMA. 2002;288:1882-1888. Pr
MJ. Long-term effects of weight loss and dietary so- Medical Association; National Optometric Associa- 10. Neal B, MacMahon S, Chapman N. Effects of ACE
dium reduction on incidence of hypertension. Hyper- tion; National Stroke Association; NHLBI Ad Hoc Com- inhibitors, calcium antagonists, and other blood- tension. 2000;35:544-549. F
mittee on Minority Populations; Society for Nutrition pressure-lowering drugs. Lancet. 2000;356:1955- 25. Sacks FM, Svetkey LP, Vollmer WM, et al, for the
Education; The Society of Geriatric Cardiology. Fed- DASH-Sodium Collaborative Research Group. Ef- eral Agencies: Agency for Healthcare Research and Qual- 11. Ogden LG, He J, Lydick E, Whelton PK. Long-
fects on blood pressure of reduced dietary sodium and ity; Centers for Medicare and Medicaid Services; Depart- term absolute benefit of lowering blood pressure in the Dietary Approaches to Stop Hypertension (DASH) ment of Veterans Affairs; Health Resources and Services hypertensive patients according to the JNC VI risk strati- diet. N Engl J Med. 2001;344:3-10. Ra
Administration; National Center for Health Statistics; fication. Hypertension. 2000;35:539-543. X
26. Vollmer WM, Sacks FM, Ard J, et al. Effects of
National Heart, Lung, and Blood Institute; National Insti- 12. Cherry DK, Woodwell DA. National Ambulatory
diet and sodium intake on blood pressure. Ann In- tute of Diabetes and Digestive and Kidney Diseases.
Medical Care Survey: 2000 summary. Advance Data. tern Med. 2001;135:1019-1028. Ra
Acknowledgment: We appreciate the assistance of
2002;328:1-32. Pr
27. Chobanian AV, Hill M. National Heart, Lung, and
Carol Creech, MILS, and Gabrielle Gessner, BS, from 13. Izzo JL Jr, Levy D, Black HR. Clinical Advisory State-
Blood Institute Workshop on Sodium and Blood Pres- American Institutes for Research Health Program, Sil- ment: importance of systolic blood pressure in older sure: a critical review of current scientific evidence.
Americans. Hypertension. 2000;35:1021-1024. Pr
Hypertension. 2000;35:858-863. Pr
2003 American Medical Association. All rights reserved.
(Reprinted) JAMA, May 21, 2003—Vol 289, No. 19 2571
28. Kelley GA, Kelley KS. Progressive resistance ex-
dysfunction after myocardial infarction. N Engl J Med. 63. Lindholm LH, Ibsen H, Dahlof B, et al. Cardio-
ercise and resting blood pressure. Hypertension. 2000; 1995;333:1670-1676. Ra
vascular morbidity and mortality in patients with dia- 35:838-843. M
47. Cohn JN, Tognoni G. A randomized trial of the
betes in the Losartan Intervention For Endpoint re- 29. Whelton SP, Chin A, Xin X, He J. Effect of aero-
angiotensin-receptor blocker valsartan in chronic heart duction in hypertension study (LIFE). Lancet. 2002; bic exercise on blood pressure. Ann Intern Med. 2002; failure. N Engl J Med. 2001;345:1667-1675. Ra
359:1004-1010. Ra
136:493-503. M
48. Pitt B, Zannad F, Remme WJ, et al, for Random-
64. Bakris GL, Williams M, Dworkin L, et al, for Na-
30. Xin X, He J, Frontini MG, et al. Effects of alcohol
ized Aldactone Evaluation Study Investigators. The tional Kidney Foundation Hypertension and Diabe- reduction on blood pressure. Hypertension. 2001;38: effect of spironolactone on morbidity and mortality tes Executive Committees Working Group. Preserv- 1112-1117. M
in patients with severe heart failure. N Engl J Med. ing renal function in adults with hypertension and 31. Black HR, Elliott WJ, Grandits G, et al. Principal
1999;341:709-717. Ra
diabetes. Am J Kidney Dis. 2000;36:646-661. Pr
results of the Controlled Onset Verapamil Investiga- 49. Braunwald E, Antman EM, Beasley JW, et al. ACC/
65. Bakris GL, Weir MR. Angiotensin-converting en-
tion of Cardiovascular End Points (CONVINCE) trial.
AHA 2002 guideline update for the management of zyme inhibitor-associated elevations in serum creati- JAMA. 2003;289:2073-2082. Ra
patients with unstable angina and non-ST-segment nine. Arch Intern Med. 2000;160:685-693. M
32. Dahlof B, Devereux RB, Kjeldsen SE, et al. Car-
elevation myocardial infarction. J Am Coll Cardiol. 66. National Cholesterol Education Program. Third Re-
diovascular morbidity and mortality in the Losartan In- 2002;40:1366-1374. Pr
port of the National Cholesterol Education Program tervention For Endpoint Reduction in Hypertension 50. ␤-Blocker Heart Attack Trial Research Group. A
(NCEP) Expert Panel on Detection, Evaluation, and Study (LIFE). Lancet. 2002;359:995-1003. Ra
randomized trial of propranolol in patients with acute Treatment of High Blood Cholesterol in Adults (Adult 33. The ALLHAT Officers and Coordinators for the ALL-
myocardial infarction, I: mortality results. JAMA. 1982; Treatment Panel III) final report. Circulation. 2002; HAT Collaborative Research Group. Major outcomes in 247:1707-1714. Ra
106:3143-3421. Pr
high-risk hypertensive patients randomized to angio- 51. Hager WD, Davis BR, Riba A, et al, for the Sur-
67. Kjeldsen SE, Dahlof B, Devereux RB, et al. Ef-
tensin-converting enzyme inhibitor or calcium channel vival and Ventricular Enlargement (SAVE) Investiga- fects of losartan on cardiovascular morbidity and mor- blocker vs diuretic. JAMA. 2002;288:2981-2997. Ra
tors. Absence of a deleterious effect of calcium chan- tality in patients with isolated systolic hypertension and 34. The Heart Outcomes Prevention Evaluation Study
nel blockers in patients with left ventricular dysfunction left ventricular hypertrophy: a Losartan Intervention Investigators. Effects of an angiotensin-converting- after myocardial infarction: the SAVE Study Experi- for Endpoint Reduction (LIFE) substudy. JAMA. 2002; enzyme inhibitor, ramipril, on cardiovascular events ence. Am Heart J. 1998;135:406-413. Ra
288:1491-1498. Ra
in high-risk patients. N Engl J Med. 2000;342:145- 52. The Capricorn Investigators. Effect of carvedilol
68. Hyman DJ, Pavlik VN. Characteristics of patients
on outcome after myocardial infarction in patients with with uncontrolled hypertension in the United States.
35. PROGRESS Collaborative Group. Randomised trial
left-ventricular dysfunction: the CAPRICORN ran- N Engl J Med. 2001;345:479-486. X
of a perindopril-based blood-pressure-lowering regi- domised trial. Lancet. 2001;357:1385-1390. Ra
69. Staessen JA, Wang J. Blood-pressure lowering for
men among 6105 individuals with previous stroke or 53. Pitt B, Remme W, Zannad F, et al. Eplerenone, a
the secondary prevention of stroke [commentary]. Lan- transient ischaemic attack. Lancet. 2001;358:1033- selective aldosterone blocker, in patients with left ven- tricular dysfunction after myocardial infarction. N Engl 70. Di Bari M, Pahor M, Franse LV, et al. Dementia
36. Wing LMH, Reid CM, Ryan P, et al, for Second
J Med. 2003;348:1309-1321. Ra
and disability outcomes in large hypertension trials: Australian National Blood Pressure Study Group. A 54. UK Prospective Diabetes Study Group. Efficacy of
lessons learned from the Systolic Hypertension in the comparison of outcomes with angiotensin-converting- atenolol and captopril in reducing risk of macrovas- Elderly Program (SHEP) trial. Am J Epidemiol. 2001; enzyme inhibitors and diuretics for hypertension in the cular and microvascular complications in type 2 dia- 153:72-78. Ra
elderly. N Engl J Med. 2003;348:583-592. Ra
betes: UKPDS 39. BMJ. 1998;317:713-720. Ra
71. Writing Group for the Women’s Health Initiative
37. Psaty BM, Smith NL, Siscovick DS, et al. Health
55. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The
Investigators. Risks and benefits of estrogen plus pro- outcomes associated with antihypertensive therapies effect of angiotensin-converting-enzyme inhibition on gestin in healthy postmenopausal women. JAMA. 2002; used as first-line agents. JAMA. 1997;277:739-745.
diabetic nephropathy: The Collaborative Study Group.
288:321-333. Ra
N Engl J Med. 1993;329:1456-1462. Ra
72. National High Blood Pressure Education Pro-
38. Physicians’ Desk Reference. 57th ed. Oradell, NJ:
56. Brenner BM, Cooper ME, de Zeeuw D, et al. Ef-
gram. Report of the National High Blood Pressure Edu- fects of losartan on renal and cardiovascular out- cation Program Working Group on high blood pres- 39. Psaty BM, Manolio TA, Smith NL, et al. Time trends
comes in patients with type 2 diabetes and nephropa- sure in pregnancy. Am J Obstet Gynecol. 2000;183: in high blood pressure control and the use of antihy- thy. N Engl J Med. 2001;345:861-869. Ra
S1-S22. Pr
pertensive medications in older adults. Arch Intern Med. 57. Lewis EJ, Hunsicker LG, Clarke WR, et al. Reno-
73. National High Blood Pressure Education Pro-
2002;162:2325-2332. X
protective effect of the angiotensin-receptor antago- gram Working Group on Hypertension Control in Chil- 40. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA
nist irbesartan in patients with nephropathy due to type dren and Adolescents. Update on the 1987 Task Force guidelines for the evaluation and management of chronic 2 diabetes. N Engl J Med. 2001;345:851-860. Ra
Report on high blood pressure in children and ado- heart failure in the adult. J Am Coll Cardiol. 2001;38: 58. The GISEN (Gruppo Italiano di Studi Epidemio-
lescents. Pediatrics. 1996;98:649-658. Pr
2101-2113. Pr
logici in Nefrologia) Group. Randomised placebo- 74. Barlow SE, Dietz WH. Obesity evaluation and
41. Tepper D. Frontiers in congestive heart failure:
controlled trial of effect of ramipril on decline in glo- treatment: expert committee recommendations.
effect of metoprolol CR/XL in chronic heart failure.
merular filtration rate and risk of terminal renal failure Pediatrics. 1998;102:E29. Pr
Congest Heart Fail. 1999;5:184-185. Ra
in proteinuric, non-diabetic nephropathy. Lancet. 1997; 75. Barrier PA, Li JT, Jensen NM. Two words to im-
42. Packer M, Coats AJ, Fowler MB, et al. Effect of
349:1857-1863. Ra
prove physician-patient communication: what else? carvedilol on survival in severe chronic heart failure.
59. Wright JT Jr, Agodoa L, Contreras G, et al. Suc-
Mayo Clin Proc. 2003;78:211-214. Pr
N Engl J Med. 2001;344:1651-1658. Ra
cessful blood pressure control in the African Ameri- 76. Betancourt JR, Carrillo JE, Green AR. Hyperten-
43. CIBIS Investigators and Committees. A random-
can Study of Kidney Disease and Hypertension. Arch sion in multicultural and minority populations. Curr Hy- ized trial of beta-blockade in heart failure: the Car- Intern Med. 2002;162:1636-1643. Ra
diac Insufficiency Bisoprolol Study (CIBIS). Circula- 60. Bakris GL, Weir MR, for the Study of Hyperten-
77. Phillips LS, Branch WT, Cook CB, et al. Clinical
tion. 1994;90:1765-1773. Ra
sion and Efficacy of Lotrel in Diabetes (SHIELD) In- inertia. Ann Intern Med. 2001;135:825-834.
44. The SOLVD Investigators. Effect of enalapril on
vestigators. Achieving goal blood pressure in pa- 78. Balas EA, Weingarten S, Garb CT, et al. Improv-
survival in patients with reduced left ventricular ejec- tients with type 2 diabetes. J Clin Hypertens ing preventive care by prompting physicians. Arch tion fractions and congestive heart failure. N Engl (Greenwich). 2003;5:201-210. Ra
Intern Med. 2000;160:301-308. C
J Med. 1991;325:293-302. Ra
61. Antithrombotic Trialist Collaboration. Collabora-
79. Boulware LE, Daumit GL, Frick KD, et al. An evi-
45. The Acute Infarction Ramipril Efficacy (AIRE) Study
tive meta-analysis of randomised trials of antiplatelet dence-based review of patient-centered behavioral in- Investigators. Effect of ramipril on mortality and mor- therapy for prevention of death, myocardial infarc- terventions for hypertension. Am J Prev Med. 2001; bidity of survivors of acute myocardial infarction with tion, and stroke in high risk patients. BMJ. 2002;324: 21:221-232. Pr, M
clinical evidence of heart failure. Lancet. 1993;342: 80. Hill MN, Miller NH. Compliance enhancement: a
821-828. Ra
62. Pfeffer MA, Braunwald E, Moye LA, et al, for the
call for multidisciplinary team approaches. Circula- 46. Kober L, Torp-Pedersen C, Carlsen JE, et al, for
SAVE Investigators. Effect of captopril on mortality and Trandolapril Cardiac Evaluation (TRACE) Study Group.
morbidity in patients with left ventricular dysfunc- 81. Flegal KM, Carroll MD, Ogden CL, Johnson CL.
A clinical trial of the angiotensin-converting-enzyme tion after myocardial infarction. N Engl J Med. 1992; Prevalence and trends in obesity among US adults, inhibitor trandolapril in patients with left ventricular 327:669-677. Ra
1999-2000. JAMA. 2002;288:1723-1727. X
2572 JAMA, May 21, 2003—Vol 289, No. 19 (Reprinted)
2003 American Medical Association. All rights reserved.

Source: http://www.ucs.br/ucs/tplLigaCardiologia/centro/cecs/ligas/liga_cardiologia/acoes/jnc7.pdf


Trial Scenarios for Monitoring Pilot randomised trial of streptokinase, aspirin and heparin in acute myocardial infarction1 Background: Several small trials have been undertaken of IV streptokinase in acute MI, often followed by an anticoagulant, but there was considerable heterogeneity of effect and use of these treatments is very variable. Design: 2x2x2 factorial RCT to gain exp

Note: pursuant to fed

NOTE: Pursuant to Fed. Cir. R. 47.6, this disposition is not citable as precedent. It is a public record. United States Court of Appeals for the Federal Circuit DECIDED: July 13, 2005 ___________________________ Before MAYER, LOURIE, and BRYSON, Circuit Judges. Opinion for the court filed by Circuit Judge BRYSON. Circuit Judge MAYER dissents. BRYSON, Circuit Judge. Teva Pharmaceuticals US

Copyright © 2010-2014 Drug Shortages pdf